Creating a "Prosurvival Phenotype" Through Histone Deacetylase Inhibition: Past, Present, and Future.

ABSTRACT: Traumatic injuries and their sequelae represent a major source of mortality in the United States and globally. Initial treatment for shock, traumatic brain injury, and polytrauma is limited to resuscitation fluids to replace lost volume. To date, there are no treatments with inherent prosurvival properties. Our laboratory has investigated the use of histone deacetylase inhibitors (HDACIs) as pharmacological agents to improve survival. This class of drugs acts through posttranslational protein modifications and is a direct regulator of chromatin structure and function, as well as the function of numerous cytoplasmic proteins. In models of hemorrhagic shock and polytrauma, administration of HDACIs offers a significant survival advantage, even in the absence of fluid resuscitation. Positive r

SUBMITTER: Halaweish I 

PROVIDER: S-EPMC4492909 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature